The Myelin-Weighted Connectome in Parkinson's Disease.
Parkinson's disease
connectome
myelin
Journal
Movement disorders : official journal of the Movement Disorder Society
ISSN: 1531-8257
Titre abrégé: Mov Disord
Pays: United States
ID NLM: 8610688
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
22
11
2021
received:
30
03
2021
accepted:
23
11
2021
pubmed:
23
12
2021
medline:
20
4
2022
entrez:
22
12
2021
Statut:
ppublish
Résumé
Even though Parkinson's disease (PD) is typically viewed as largely affecting gray matter, there is growing evidence that there are also structural changes in the white matter. Traditional connectomics methods that study PD may not be specific to underlying microstructural changes, such as myelin loss. The primary objective of this study is to investigate the PD-induced changes in myelin content in the connections emerging from the basal ganglia and the brainstem. For the weighting of the connectome, we used the longitudinal relaxation rate as a biologically grounded myelin-sensitive metric. We computed the myelin-weighted connectome in 35 healthy control subjects and 81 patients with PD. We used partial least squares to highlight the differences between patients with PD and healthy control subjects. Then, a ring analysis was performed on selected brainstem and subcortical regions to evaluate each node's potential role as an epicenter for disease propagation. Then, we used behavioral partial least squares to relate the myelin alterations with clinical scores. Most connections (~80%) emerging from the basal ganglia showed a reduced myelin content. The connections emerging from potential epicentral nodes (substantia nigra, nucleus basalis of Meynert, amygdala, hippocampus, and midbrain) showed significant decrease in the longitudinal relaxation rate (P < 0.05). This effect was not seen for the medulla and the pons. The myelin-weighted connectome was able to identify alteration of the myelin content in PD in basal ganglia connections. This could provide a different view on the importance of myelination in neurodegeneration and disease progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Sections du résumé
BACKGROUND
Even though Parkinson's disease (PD) is typically viewed as largely affecting gray matter, there is growing evidence that there are also structural changes in the white matter. Traditional connectomics methods that study PD may not be specific to underlying microstructural changes, such as myelin loss.
OBJECTIVE
The primary objective of this study is to investigate the PD-induced changes in myelin content in the connections emerging from the basal ganglia and the brainstem. For the weighting of the connectome, we used the longitudinal relaxation rate as a biologically grounded myelin-sensitive metric.
METHODS
We computed the myelin-weighted connectome in 35 healthy control subjects and 81 patients with PD. We used partial least squares to highlight the differences between patients with PD and healthy control subjects. Then, a ring analysis was performed on selected brainstem and subcortical regions to evaluate each node's potential role as an epicenter for disease propagation. Then, we used behavioral partial least squares to relate the myelin alterations with clinical scores.
RESULTS
Most connections (~80%) emerging from the basal ganglia showed a reduced myelin content. The connections emerging from potential epicentral nodes (substantia nigra, nucleus basalis of Meynert, amygdala, hippocampus, and midbrain) showed significant decrease in the longitudinal relaxation rate (P < 0.05). This effect was not seen for the medulla and the pons.
CONCLUSIONS
The myelin-weighted connectome was able to identify alteration of the myelin content in PD in basal ganglia connections. This could provide a different view on the importance of myelination in neurodegeneration and disease progression. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Identifiants
pubmed: 34936123
doi: 10.1002/mds.28891
pmc: PMC9303520
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
724-733Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 213722/Z/18/Z
Pays : United Kingdom
Informations de copyright
© 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Références
Front Aging Neurosci. 2015 May 21;7:90
pubmed: 26052284
Hum Brain Mapp. 2014 May;35(5):1921-9
pubmed: 23843285
Neuroimage. 2003 Oct;20(2):870-88
pubmed: 14568458
Neuroimage. 2018 Nov 15;182:351-359
pubmed: 28917698
Brain Struct Funct. 2020 Nov;225(8):2387-2402
pubmed: 32816112
Neuroimage. 2015 Jun;113:184-95
pubmed: 25776214
J Neurosci. 2017 Oct 11;37(41):9808-9818
pubmed: 29021298
Brain. 2020 Oct 1;143(10):3077-3088
pubmed: 32830221
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Mov Disord. 2003 Jul;18(7):784-90
pubmed: 12815657
Neuroimage. 2019 May 15;192:178-194
pubmed: 30851444
Science. 2012 Nov 16;338(6109):949-53
pubmed: 23161999
Neurology. 1967 May;17(5):427-42
pubmed: 6067254
J Magn Reson Imaging. 2019 Jul;50(1):164-174
pubmed: 30444020
Biochim Biophys Acta. 2012 Feb;1822(2):261-85
pubmed: 22024360
Neuroimage. 2010 Jan 15;49(2):1271-81
pubmed: 19819338
Neurology. 2016 Dec 13;87(24):2540-2545
pubmed: 27837003
Neuron. 2009 Apr 16;62(1):42-52
pubmed: 19376066
CNS Neurosci Ther. 2015 Oct;21(10):837-45
pubmed: 25899584
Neuroimage. 2016 Nov 15;142:394-406
pubmed: 27523449
Nature. 2013 Sep 5;501(7465):45-51
pubmed: 24005412
Mov Disord. 2012 Jan;27(1):90-7
pubmed: 21850668
J Neurosci. 2016 Apr 06;36(14):4056-66
pubmed: 27053212
Magn Reson Med. 2016 Nov;76(5):1582-1593
pubmed: 26599599
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
J Clin Sleep Med. 2014 Sep 15;10(9):1039-40
pubmed: 25221449
J Am Geriatr Soc. 2009 Feb;57(2):304-8
pubmed: 19170786
Lancet Neurol. 2018 Jul;17(7):618-628
pubmed: 29866443
Nat Rev Neurosci. 2009 Mar;10(3):186-98
pubmed: 19190637
Annu Rev Psychol. 2013;64:499-525
pubmed: 22804773
J Clin Neurosci. 1996 Jan;3(1):52-60
pubmed: 18644264
Neuroimage. 2019 Nov 15;202:116137
pubmed: 31473352
PLoS Biol. 2019 Nov 21;17(11):e3000495
pubmed: 31751329
J Neurosci. 2010 Nov 24;30(47):15915-26
pubmed: 21106830
Neuroimage. 2012 Sep;62(3):1924-38
pubmed: 22705374
Acta Neuropathol. 1994;88(6):493-500
pubmed: 7879596
Brain Struct Funct. 2017 Aug;222(6):2487-2505
pubmed: 28168364
Neuropathol Appl Neurobiol. 2007 Dec;33(6):599-614
pubmed: 17961138
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
Elife. 2015 Sep 07;4:
pubmed: 26344547
Neuroimage Clin. 2021;30:102587
pubmed: 33610097
AJNR Am J Neuroradiol. 2008 Mar;29(3):501-5
pubmed: 18202242
Neuroimage. 2014 Jun;93 Pt 1:95-106
pubmed: 24607447
PLoS One. 2019 Jul 3;14(7):e0218089
pubmed: 31269041
IEEE Trans Med Imaging. 2010 Jun;29(6):1310-20
pubmed: 20378467
Neurology. 2021 Jan 19;96(3):e460-e471
pubmed: 33277419
Neuroimage. 2011 May 15;56(2):455-75
pubmed: 20656037
Trends Neurosci. 2013 Oct;36(10):561-9
pubmed: 23876425
Neuroimage. 2010 Oct 1;52(4):1175-80
pubmed: 20677376
Neuroimage. 2004;23 Suppl 1:S250-63
pubmed: 15501095
Front Neurol. 2018 May 11;9:334
pubmed: 29867741
Mov Disord. 2017 Jun;32(6):874-883
pubmed: 28597560
Brain. 2018 May 1;141(5):1501-1516
pubmed: 29701787
Neurosci Biobehav Rev. 2000 Aug;24(6):655-68
pubmed: 10940440
Brain Struct Funct. 2014 Sep;219(5):1513-26
pubmed: 24135772
Neuroimage. 2019 Apr 15;190:79-93
pubmed: 30465864
Nat Rev Neurosci. 2010 Nov;11(11):760-72
pubmed: 20944662
Mov Disord. 2017 May;32(5):693-704
pubmed: 28164375
Mov Disord. 2015 Aug;30(9):1229-36
pubmed: 25920732
Adv Anat Embryol Cell Biol. 2009;201:1-119
pubmed: 19230552
Magn Reson Med. 2016 Nov;76(5):1574-1581
pubmed: 26745823
Sci Rep. 2016 Nov 09;6:36669
pubmed: 27827408
Brain Pathol. 2015 Mar;25(2):121-35
pubmed: 24995389
Elife. 2020 Oct 21;9:
pubmed: 33084576
Neuroimage. 2016 Jan 15;125:1063-1078
pubmed: 26481672
Sci Rep. 2019 Sep 18;9(1):13522
pubmed: 31534143
PLoS One. 2014 Jun 16;9(6):e99676
pubmed: 24932514
Netw Neurosci. 2021 Apr 27;5(2):358-372
pubmed: 34189369
Neuroimage. 2014 Dec;103:411-426
pubmed: 25109526
Brain. 2013 Apr;136(Pt 4):1128-38
pubmed: 23466394
Mov Disord. 2013 Apr;28(4):447-54
pubmed: 23144002
Brain. 2013 Jul;136(Pt 7):2120-9
pubmed: 23801736
Neuroimage. 2013 Apr 15;70:402-9
pubmed: 23296185
Neuroimage. 2012 Aug 15;62(2):774-81
pubmed: 22248573
PLoS One. 2016 Oct 5;11(10):e0163774
pubmed: 27706215
Nat Commun. 2018 Jan 2;9(1):12
pubmed: 29295991
J Neuropathol Exp Neurol. 2006 Aug;65(8):808-15
pubmed: 16896314
AJNR Am J Neuroradiol. 2019 Jul;40(7):1162-1169
pubmed: 31221631